Vildagliptin 100 mg SR once daily dose is equally effective and safe as 50 mg twice daily dose

      Vildagliptin 100 mg sustained release (SR) once daily dose is equally effective and safe as 50 mg twice daily dose in terms of reducing HbA1c, FPG, and PPPG when it is used along with metformin 1000 mg in patients with type 2 diabetes. The study published in ‘National Journal of Physiology, Pharmacy and Pharmacology’ that compared the effectiveness and safety of vildagliptin 50 mg twice daily dose with vildagliptin 100 mg sustained release tablet (SR) once daily in patients with type 2 diabetes and uncontrolled with metformin monotherapy.

      The study cohort included 126 adult patients aged between 18 – 60 years and newly diagnosed type 2 diabetes with HbA1c >6.5 and < 8. They were randomized in two groups; one group received metformin 1000 mg/day in two divided dose and tablet vildagliptin 50 mg 2 times daily, while the other group received metformin 1000 mg/day in two divided dose along with vildagliptin 100 mg SR once daily. Fasting plasma glucose (FPG), postprandial plasma glucose (PPPG), and glycated hemoglobin (HbA1c), were measured at baseline, on week 4, week 8, and week 12 visits. Liver function test (SGOT, SGPT, Serum Bilirubin), kidney function test (electrolytes, serum urea, serum creatinine), and body weight also measured in first visit and in 12th week.

     The results showed significant decrease in HbA1c, FPG, and PPPG at 12 week from their respective baseline values. There was observed no statistically significant alteration of liver enzymes and in serum bilirubin level in both groups. The study concluded that Vildagliptin 100 mg SR once daily dose is equally effective and safe as 50 mg twice daily dose in terms of reducing HbA1c, FPG, and PPPG when it is used along with metformin 1000 mg.

Read More